Table 1.
Baseline patient characteristics
| Stage 1 | Stage 2 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Navoximod 400 mg (N = 3) | Navoximod 600 mg (N = 4) | Navoximod 1000 mg (N = 3) | Stage 1 total (N = 10) | Navoximod 200 mg + Atezolizumab (N = 3) | Navoximod 400 mg + Atezolizumab (N = 3) | Navoximod 600 mg + Atezolizumab (N = 3) | Navoximod 1000 mg + Atezolizumab (N = 1) | Stage 2 total (N = 10) | |
| Age, years | |||||||||
| Median | 68 | 62 | 54 | 61.5 | 58 | 68 | 66 | 58 | 63.5 |
| Range | 64–74 | 48–75 | 52–59 | 48–75 | 57–70 | 56–70 | 61–69 | – | 56–70 |
| Sex, n | |||||||||
| Male | 2 | 2 | 0 | 4 | 1 | 2 | 3 | 1 | 7 |
| Female | 1 | 2 | 3 | 6 | 2 | 1 | 0 | 0 | 3 |
| ECOG PS, n | |||||||||
| 0 | 0 | 3 | 3 | 6 | 1 | 3 | 3 | 0 | 7 |
| 1 | 3 | 1 | 0 | 4 | 2 | 0 | 0 | 1 | 3 |
| No. of prior systemic treatments, n | |||||||||
| Median | 2 | 4 | 4 | 3 | 6 | 1 | 3 | 4 | 4 |
| Range | 2–3 | 2–6 | 1–11 | 1–11 | 4–15 | 1–6 | 3–4 | – | 1–15 |
ECOG Eastern Cooperative Oncology Group, PS performance status